A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

PHASE2TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

September 25, 2024

Study Completion Date

September 25, 2024

Conditions
Sleep Apnea
Interventions
DRUG

Danavorexton

Danavorexton IV infusion.

DRUG

Placebo

Placebo matching danavorexton IV infusion.

Trial Locations (19)

33165

Medical Research Center - Clinic/Outpatient Facility, Miami

60622

Rush University, Chicago

90048

Cedars Sinai Medical Hospital, West Hollywood

35660-6334

Helen Keller Hospital, Sheffield

85054-4502

Mayo Clinic - PPDS - Hospital, Phoenix

92037-1300

UCSD, La Jolla

32224-1865

Mayo Clinic Jacksonville - PPDS, Jacksonville

33136-1005

University of Miami - Leonard M. Miller School of Medicine, Miami

33606-3601

University of South Florida, Tampa

33331-3609

Cleveland Clinic Florida, Weston

40202-3700

University of Louisville - Hospital, Louisville

02115-6110

Brigham and Womens Hospital, Boston

09061

Inspira Health, Mullica Hill

11501-3893

NYU Langone, Mineola

11794-0001

Stony Brook University Medical Center, Stony Brook

44111-5612

Fairview Hospital, Cleveland

44195-0001

Cleveland Clinic Hospital, Cleveland

43210-1240

Ohio State University Wexner Medical Center, Columbus

53226-3522

The Medical College of Wisconsin, Inc., Milwaukee

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY